FOLH1 and neoplasm: A notable diagnostic consideration is the compound’s PSMA-specificity, which—while advantageous for tumour targeting—may lead to false-positive interpretations due to physiological PSMA expression in other tissues including bladder transitional cell carcinoma, renal cell carcinoma, and colonic carcinoma [112].